Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: Overlapping effects or limited therapeutic opportunity?

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Mancuso, Renzo ^a   Del Valle, Jaume ^a   Morell, Marta ^a   Pallás, Mercé ^a   Osta, Rosario ^b   Navarro, Xavier ^a,c  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

AMPK; Amyotrophic lateral sclerosis; Combined therapy; Motoneuron disease; PRE 084; Resveratrol; Sigma 1 receptor; Sirtuin 1

Indexed keywords

1 PHENYLCYCLOHEXANECARBOXYLIC ACID 2 MORPHOLINOETHYL ESTER; COPPER ZINC SUPEROXIDE DISMUTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; RESVERATROL; SIRTUIN 1;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BRAIN MITOCHONDRION; DISEASE COURSE; DRUG POTENTIATION; FEMALE; HISTOLOGY; IMMUNOREACTIVITY; LOCOMOTION; MALE; MICROGLIA; MOTONEURON; MOTOR NERVE CONDUCTION; MOTOR PERFORMANCE; MOUSE; MSOD1 MOUSE; MUSCLE ACTION POTENTIAL; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; ROTAROD TEST; SPINAL CORD MOTONEURON; SPINAL CORD VENTRAL HORN; SURVIVAL; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADENYLATE KINASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DRUG SYNERGISM; MICE; MICE, TRANSGENIC; MORPHOLINES; NEURAL CONDUCTION; PHOSPHORYLATION; PROTEIN KINASE C; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SIGMA; ROTAROD PERFORMANCE TEST; SIRTUIN 1; STILBENES; SUPEROXIDE DISMUTASE;

EID: 84901697170     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-78     Document Type: Article

References (67)

1. Amyotrophic lateral sclerosis. Wijesekera LC, Leigh PN, Orphanet J Rare Dis 2009 4 3 10.1186/1750-1172-4-3 19192301
2. Amyotrophic lateral sclerosis. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrel JR, Zoing MC, The Lancet 2011 377 942 55 10.1016/S0140-6736(10)61156-7
3. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Rosen DR, Nature 1993 364 362 8332197 (Pubitemid 23265284)
4. Rodent models of amyotrophic lateral sclerosis. McGoldrick P, Joyce PI, Fisher EMC, Greensmith L, BBA-Molecular Basis of Disease 1832 2013 1421 1436
5. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW, Proc Natl Acad Sci USA 1995 92 689 93 10.1073/pnas.92.3.689 7846037
6. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Science 1994 264 1772 5 10.1126/science.8209258 8209258 (Pubitemid 24227760)
7. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, Goolsby H, Fontaine BA, Lemay N, McKenna-Yasek D, Frosch MP, Agar JN, Julien JP, Brady ST, Brown RH, Nat Neurosci 2010 13 1396 403 10.1038/nn.2660 20953194
8. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Hayashi T, Su T-P, Cell 2007 131 596 610 10.1016/j.cell.2007.08.036 17981125 (Pubitemid 350017760)
9. Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system. Alonso G, Phan V-L, Guillemain I, Saunier M, Legrand A, Anoal M, Maurice T, Neuroscience 2000 97 155 70 10.1016/S0306-4522(00)00014-2 10771347 (Pubitemid 30195885)
10. Immunohistochemical localization of the sigma1-receptor in oligodendrocytes in the rat central nervous system. Palacios G, Muro A, Vela JM, Molina-Holgado E, Guitart X, Ovalle S, Zamanillo D, Brain Res 2003 961 92 9 10.1016/S0006-8993(02)03892-1 12535781 (Pubitemid 36084473)
11. Sigma receptor agonist 2-(4-morpholinethyl)1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury. Penas C, Pascual-Font A, Mancuso R, Forés J, Casas C, Navarro X, J Neurotrauma 2011 28 831 40 10.1089/neu.2010.1674 21332255
12. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Mavlyutov TA, Epstein ML, Andersen KA, Ziskind-Conhaim L, Ruoho AE, Neuroscience 2010 167 247 55 10.1016/j.neuroscience.2010.02.022 20167253
13. Sigma receptors suppress multiple aspects of microglial activation. Hall AA, Herrera Y, Ajmo CT Jr, Cuevas J, Pennypacker KR, Glia 2009 57 744 54 10.1002/glia.20802 19031439
14. Activation of the ζ receptor 1 suppresses NMDA responses in rat retinal ganglion cells. Zhang X-J, Liu L-L, Jiang S-X, Zhong Y-M, Yang X-L, Neuroscience 2011 177 12 22 21211548
15. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Aydar E, Palmer CP, Klyachko VA, Jackson MB, Neuron 2002 34 399 410 10.1016/S0896-6273(02)00677-3 11988171 (Pubitemid 34465498)
16. σ Receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. Zhang H, Cuevas J, J Pharmacol Exp Ther 2005 313 1387 96 10.1124/jpet.105.084152 15764734 (Pubitemid 40727046)
17. The pharmacology of sigma-1 receptors. Maurice T, Su T-P, Pharmacol Ther 2009 124 195 206 10.1016/j.pharmthera.2009.07.001 19619582
18. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Al-Saif A, Al-Mohanna F, Bohlega S, Ann Neurol 2011 70 913 9 10.1002/ana.22534 21842496
19. Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats. Allahtavakoli M, Jarrott B, Brain Res Bull 2011 85 219 24 10.1016/j.brainresbull.2011.03.019 21453760
20. SA4503, a sigma-1 receptor agonist, prevents cultured cortical neurons from oxidative stress-induced cell death via suppression of MAPK pathway activation and glutamate receptor expression. Tuerxun T, Numakawa T, Adachi N, Kumamaru E, Kitazawa H, Kudo M, Kanugi H, Neurosci Lett 2010 469 303 8 10.1016/j.neulet.2009.12.013 20025928
21. Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats. Ajmo CT Jr, Vernon DOL, Collier L, Pennypacker KR, Cuevas J, Curr Neurovasc Res 2006 3 89 98 10.2174/156720206776875849 16719792 (Pubitemid 43778702)
22. Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice. Mancuso R, Oliván S, Rando A, Casas C, Osta R, Navarro X, Neurotherapeutics 2012 9 814 26 10.1007/s13311-012-0140-y 22935988
23. Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Porquet D, Casadesús G, Bayod S, Vicente A, Canudas AM, Vilaplana J, Pelegrí C, Sanfeliu C, Camins A, Pallás M, del Valle J, Age (Dordr) 2013 35 1851 65 10.1007/s11357-012-9489-4 23129026
24. Resveratrol-activated AMPK/SIRT1/Autophagy in cellular models of parkinson's disease. Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, Jankovic J, Pan T, Neurosignals 2011 19 163 74 10.1159/000328516 21778691
25. Resveratrol improves neuron protection and functional recovery in rat model of spinal cord injury. Liu C, Shi Z, Fan L, Zhang C, Wang K, Wang B, Brain Res 2011 1374 100 9 21111721
26. A dietary polyphenol resveratrol acts to provide neuroprotection in recurrent stroke models by regulating AMPK and SIRT1 signaling, thereby reducing energy requirements during ischemia. Wang L-M, Wang Y-J, Cui M, Luo W-J, Wang X-J, Barber PA, Chen ZY, Eur J Neurosci 2013 37 1669 81 10.1111/ejn.12162 23461657
27. Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Wang J, Zhang Y, Tang L, Zhang N, Fan D, Neurosci Lett 2011 503 250 5 10.1016/j.neulet.2011.08.047 21896316
28. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, EMBO J 2007 26 3169 79 10.1038/sj.emboj.7601758 17581637 (Pubitemid 47057498)
29. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Price NL, Gomes AP, Ling AJY, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JD, Hubbard BP, Varela AT, Davis JG, Veramini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, del Cabo R, Baur JA, Sinclair DA, Cell Metabolism 2012 15 675 90 10.1016/j.cmet.2012.04.003 22560220
30. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Park S-J, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussing R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH, Cell 2012 148 421 33 10.1016/j.cell.2012.01.017 22304913
31. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE, Tsokos M, Alt FW, Finkel T, Proc Natl Acad Sci USA 2008 105 3374 9 10.1073/pnas. 0712145105 18296641 (Pubitemid 351723560)
32. G93A ALS mice. Mancuso R, del Valle J, Modol L, Martinez A, Granado-Serrano AB, Ramirez-Núñez O, Pallás M, Portero-Otin M, Osta R, Navarro X, Neutotherapeutics 2014 11 419 32 10.1007/s13311-013-0253-y
33. Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Ferraiuolo L, Higginbottom A, Heath PR, Barber SC, Greenald D, Kirby J, Shaw PJ, Brain 2011 134 2627 41 10.1093/brain/awr193 21908873
34. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Pasinelli P, Brown RH, Nat Rev Neurosci 2006 7 710 23 10.1038/nrn1971 16924260 (Pubitemid 44267495)
35. Resveratrol protects the brain of obese mice from oxidative damage. Rege SD, Kumar S, Wilson DN, Tamura L, Geetha T, Mathews ST, Huggins KW, Broderick TL, Babu JR, Oxid Med Cell Long 2013 4 1 7
36. Electrophysiological analysis of a murine model of motoneuron disease. Mancuso R, Santos-Nogueira E, Osta R, Navarro X, Clin Neurophysiol 2011 122 1660 70 10.1016/j.clinph.2011.01.045 21354365
37. Methods and protocols in peripheral nerve regeneration experimental research. Electrophysiological evaluation. Navarro X, Udina E, Int Rev Neurobiol 2009 87 105 26 19682635
38. Tests to assess motor phenotype in mice: a user's guide. Brooks SP, Dunnett SB, Nat Rev Neurosci 2009 10 519 29 10.1038/nrn2652 19513088
39. Evolution of gait abnormalities in SOD1(G93A) transgenic mice. Mancuso R, Oliván S, Osta R, Navarro X, Brain Res 2011 1406 65 73 21733494
40. Cytoskeletal and activity-related changes in spinal motoneurons after root avulsion. Penas C, Casas C, Robert I, Forés J, Navarro X, J Neurotrauma 2009 26 763 79 10.1089/neu.2008.0661 19331524
41. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD, Exp Neurol 2004 185 232 40 10.1016/j.expneurol. 2003.10.004 14736504 (Pubitemid 38084849)
42. The localization of motoneurons supplying the hindlimb muscles of the mouse. McHanwell S, Biscoe TJ, Philos Trans R Soc Lond, B, Biol Sci 1981 293 477 508 10.1098/rstb.1981.0082 6115428
43. Selective sigma receptor agonist 2-(4-morpholinethyl)1- phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons. Guzmán-Lenis M-S, Navarro X, Casas C, Neuroscience 2009 162 31 8 10.1016/j.neuroscience.2009.03.067 19345724
44. Calcium dysregulation in amyotrophic lateral sclerosis. Grosskreutz J, Van Den Bosch L, Keller BU, Cell Calcium 2010 47 165 74 10.1016/j.ceca.2009.12. 002 20116097
45. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W, BBA-Molecular Basis of Disease 2006 1762 1068 82 10.1016/j.bbadis.2006.05.002 16806844 (Pubitemid 44781176)
46. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Alexianu ME, Ho BK, Mohamed AH, La Bella V, Smith RG, Appel SH, Ann Neurol 1994 36 846 58 10.1002/ana.410360608 7998770 (Pubitemid 24370923)
47. The σ-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1/GluN2A NMDA receptor. Balasuriya D, Stewart AP, Edwardson JM, J Neurosci 2013 33 18219 24 10.1523/JNEUROSCI.3360-13.2013 24227730
48. 2+ entry and transient receptor potential channels by Sigma-1 receptor ligands. Amer MS, McKeown L, Tumova S, Liu R, Seymour VAL, Wilson LA, Naylor J, Greenhalgh K, Hou B, Majeed Y, Turner P, Sedo A, O'Regan DJ, Li J, Bon RS, Porter KE, Beech DJ, British J Pharmacol 2013 168 1445 55 10.1111/bph.12041
49. Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine. Kourrich S, Hayashi T, Chuang J-Y, Tsai S-Y, Su T-P, Bonci A, Cell 2013 152 236 47 10.1016/j.cell.2012.12.004 23332758
50. Lack of sigma-1 receptor exacerbates ALS progression in mice. Mavlyutov TA, Epstein ML, Verbny YI, Huerta MS, Zaitoun I, Ziskind-Conhaim L, Ruoho AE, Neuroscience 2013 240 129 34 23458708
51. Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. Mori T, Hayashi T, Hayashi E, Su T-P, PLoS ONE 2013 8 76941 10.1371/journal.pone.0076941 24204710
52. The lifetime of UDP-galactose:ceramide galactosyltransferase is controlled by a distinct endoplasmic reticulum-associated degradation (ERAD) regulated by sigma-1 receptor chaperones. Hayashi T, Hayashi E, Fujimoto M, Sprong H, Su T-P, J Biol Chem 2012 287 43156 69 10.1074/jbc.M112.380444 23105111
53. σ-1 receptor at the mitochondrial-associated endoplasmic reticulum membrane is responsible for mitochondrial metabolic regulation. Marriott K-SC, Prasad M, Thapliyal V, Bose HS, J Pharmacol Exp Ther 2012 343 578 86 10.1124/jpet.112.198168 22923735
54. Sirtuin deacetylases in neurodegenerative diseases of aging. Herskovits AZ, Guarente L, Cell Res 2013 23 746 58 10.1038/cr.2013.70 23689277
55. Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Fonseca-Kelly Z, Nassrallah M, Uribe J, Khan RS, Dine K, Dutt M, Shindler KS, Front Neurol 2012 3 84 22654783
56. Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets. Nimmagadda VK, Bever CT, Vattikunta NR, Talat S, Ahmad V, Nagalla NK, Trisler D, Judge SIV, Royal W, Chandrasekaran K, Russel JW, Makar TP, J Immunol 2013 190 4595 607 23547115
57. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, Marsh JL, Hum Mol Genet 2010 20 261 70 20952447
58. Neuroprotective properties of resveratrol in different neurodegenerative disorders. Albani D, Polito L, Signorini A, Forloni G, BioFactors 2010 36 370 6 10.1002/biof.118 20848560
59. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Jin F, Wu Q, Lu Y-F, Gong Q-H, Shi J-S, Eur J Pharmacol 2008 600 78 82 10.1016/j.ejphar.2008.10.005 18940189
60. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Araki T, Sasaki Y, Milbrandt J, Science 2004 305 1010 3 10.1126/science.1098014 15310905 (Pubitemid 39071777)
61. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Zhang F, Liu J, Shi J-S, Eur J Pharmacol 2010 636 1 7 10.1016/j.ejphar.2010.03.043 20361959
62. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Bi XL, Yang JY, Dong YX, Wang JM, Cui YH, Ikeshima T, Zhao YQ, Wu CF, Int Immunopharmacol 2005 5 185 93 10.1016/j.intimp.2004.08.008 15589480 (Pubitemid 39626704)
63. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. Candelario-Jalil E, de Oliveira A, Gräf S, Bhatia HS, Hüll M, Muñoz E, Fiebich BL, J Neuroinflamm 2007 4 25 10.1186/1742-2094-4-25 (Pubitemid 350226888)
64. Effects of resveratrol and its derivatives on lipopolysaccharide-induced microglial activation and their structure-activity relationships. Meng X-L, Yang JY, Chen G-L, Wang L-H, Zhang L-J, Wang S, Li J, Wu CF, Chem Biol Interact 2008 174 51 9 10.1016/j.cbi.2008.04.015 18513711
65. Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Wang FM, Galson DL, Roodman GD, Ouyang H, Exp Hematol 2011 39 999 1006 10.1016/j.exphem.2011.06.007 21723843
66. Progressive motor neuron impairment in an animal model of familial amyotrophic lateral sclerosis. Azzouz M, Leclerc N, Gurney M, Warter JM, Poindron P, Borg J, Muscle Nerve 1997 20 45 51 10.1002/(SICI)1097-4598(199701) 20:1<45::AID-MUS6>3.0.CO;2-H 8995582 (Pubitemid 27009468)
67. Design, power, and interpretation of studies in the standard murine model of ALS. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, Bostrom A, Theodoss J, Al Nakhala BM, Vieira FG, Ramasubbu J, Heywood JA, Amyotroph Lateral Scler 2008 9 4 15 10.1080/17482960701856300 18273714 (Pubitemid 351260367)